Stay updated on Clinical Trial of IL-2 + Nivolumab in RCC
Sign up to get notified when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.

Latest updates to the Clinical Trial of IL-2 + Nivolumab in RCC page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedExpanded the study record with added documentation references (Study Protocol and Statistical Analysis Plan), regulatory notes (FDA-regulated status), and data-sharing information, along with related MeSH terms. It also adds details about the investigators and their institution (Ajjai Alva, M.D., University of Michigan Rogel Cancer Center) to the collaborators section.SummaryDifference51%

- Check21 days agoChange DetectedThe study record page now displays a generic error page instead of its content, rendering the record unavailable. Users cannot view the study details or related information until the error is resolved.SummaryDifference17%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedA new page revision label, v3.6.4, was added in the page metadata and the previous label, v3.6.3, was removed.SummaryDifference0.1%

- Check57 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, signaling a new version of the page. This is a minor update to the page's content or layout and does not change the study data.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page metadata revision label was updated to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.1%

- Check78 days agoChange DetectedNo longer looking for participants was added, along with new help/join sections (How to Read a Study Record, Common Questions, How to Join a Study) and an Intervention/Treatment labeling update; the old Intervention / Treatment label was removed and the revision updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Clinical Trial of IL-2 + Nivolumab in RCC
Enter your email address, and we'll notify you when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.